Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis
Pooled result · Overall obesity-related cancersResult — go to the resultRelative risk 0.70 95% CI 0.54–0.89Authors' conclusion
GLP-1RA use is associated with a lower risk of several obesity-related cancers. Prospective studies are required to validate these findings and clarify underlying mechanisms.
Study context
- Population
- Adults (≥18 years) with T2D and/or obesity; searches of Embase, PubMed and CENTRAL to 20 November 2025
- Participants
- 3,960,974 adults24 studies
- Comparison
- GLP-1 RA use vs no use
- Outcome
- Obesity-related cancers (uterine, esophageal, thyroid, gastric, colorectal, liver, gallbladder, pancreatic, breast, ovarian, kidney cancers, cholangiocarcinoma, meningioma, multiple myeloma)
- Follow-up
- Within ten years
Pooled result
Overall obesity-related cancers
Relative risk
0.70
95% CI 0.54–0.89
GLP-1RAvs No GLP-1RA
RR 0.70 (95% CI 0.54–0.89)
As reported in the abstract
Further pooled results
Individual obesity-related cancers
- Reduced risks for hepatocellular carcinoma, colorectal, pancreatic, endometrial, esophageal, gallbladder, ovarian cancers and multiple myeloma
- No significant association for thyroid cancer
Original publication
Glucagon-like peptide-1 receptor agonists and the risk of obesity-related cancers: a systematic review and meta-analysis. Diabetes Res Clin Pract. Published 19 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →